Navigation Links
Stem-Cell Transplants Restored Pituitary Function in Mice
Date:11/10/2011

By Mary Brophy Marcus
HealthDay Reporter

THURSDAY, Nov. 10 (HealthDay News) -- A new study by Japanese researchers gives hope that one day people with pituitary gland failure may be able to receive transplants of stem-cell generated tissue to help restore normal function of the gland.

Without the pea-size pituitary gland, which sits at the base of the brain, the body wouldn't survive. It controls the production and function of many hormones, including ones linked to growth, fertility, stress and temperature regulation.

In the new study, published online Nov. 9 in Nature, scientists from the RIKEN Center for Developmental Biology, in Kobe, Japan, cultured embryonic stem cells from mice that then differentiated into various types of hormone-producing endocrine cells in the lab. Next, they transplanted some of the hormone-producing cell tissues (normally made by a healthy pituitary gland in animals) into mice without pituitary glands and were able to restore hormone secretion in the animals.

"We successfully induced their differentiation into mature hormone-producing cells," said study author Dr. Yoshiki Sasai, director of the Neurogenesis and Organogenesis Group at RIKEN, of the embryonic cells they used.

"In particular, adrenocorticotropin (ACTH)-producing cells were most efficiently induced. Therefore, we tested their functionality by transplanting them into mice whose pituitary glands were surgically removed. The transplantation not only recovered the hormone secretion in the mice, but also improved their activity and survival," said Sasai.

While none of the mice without pituitary glands lived longer than eight weeks, most of the grafted mice did survive past eight weeks, he said.

"It is the first study to show a realistic way of making pituitary cells in culture that could ultimately lead to transplant treatment for humans. It is pioneering and landmark research," said pituitary surge
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Does our DNA determine how well we respond to stem-cell transplantation?
2. Adult living donor liver transplants safe, study finds
3. Fecal Transplants Show Promise for Gastrointestinal Ills
4. Living donor liver transplantation improves survival over deceased donor transplants
5. Brain cell transplants win Fernström Prize
6. Ultrasound improves stem cell transplants
7. Elimination of national kidney allocation policy improves minority access to transplants
8. Half-matched transplants widen pool of donors for leukemia and lymphoma
9. Liver-cell transplants show promise in reversing genetic disease affecting liver and lungs
10. Enhanced cord blood stem cell transplants safe in long-term studies
11. Long-term study shows that kidney transplants are faring better than previously reported
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stem-Cell Transplants Restored Pituitary Function in Mice
(Date:7/24/2014)... Comparemedicalinsurance.info has released a new blog ... who have health problems. , A pre-existing medical ... clients. No medical exam life insurance plans offer a ... a lot easier. , No medical exam life ... temporary protection, while others will insure the client for ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Discount-Dress.com, an ... and women’s special occasion outfits, is doing its best ... its dresses at discounted rates, up to 75% off. ... new blog . Also, it has unveiled many ... cocktail party dresses, gorgeous lace wedding dresses, purple prom ...
(Date:7/24/2014)... July 24, 2014 Follow ... a rapidly expanding sector in the in-vitro diagnostics ... collection devices, new detection technologies, computers, and automation ... versatility, and speed. In addition to disease diagnosis, ... benefits in patient stratification, drug regimen selection, therapeutic ...
(Date:7/24/2014)... Hanover, MA (PRWEB) July 24, 2014 ... Foundation will be on hand to provide educational and ... 11th Annual Meeting next week in Colorado Springs. , ... from some of the most renowned neurointerventional research ... problem solving and innovating together (with or at) symposiums, ...
(Date:7/24/2014)... July 24, 2014 “To care for him ... and his orphan.” The inspired quote is attributed to Abraham ... of Veterans Affairs (VA). And yet the reality of Lincoln’s ... in exchange for their service in times of conflict, leaves ... represents many veterans locked in a battle they never expected ...
Breaking Medicine News(10 mins):Health News:Life Insurance Without Examinations for Clients Who Have Pre-Existing Medical Conditions 2Health News:Discount-Dress.com Announces the Launch of Its New Blog and Publishes Articles About Its Fabulous Special Occasion Dresses 2Health News:Increasing Molecular Level Understanding of Disease State & Metabolism Drives the Molecular Diagnostics Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Increasing Molecular Level Understanding of Disease State & Metabolism Drives the Molecular Diagnostics Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Increasing Molecular Level Understanding of Disease State & Metabolism Drives the Molecular Diagnostics Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Brain Aneurysm Foundation Provides Key Support to NeuroIntervential Physicians 2Health News:LawyersandSettlements.com Interviews Veterans Benefits Attorney Shanin Specter about Recent VA Hospital Reports 2Health News:LawyersandSettlements.com Interviews Veterans Benefits Attorney Shanin Specter about Recent VA Hospital Reports 3Health News:LawyersandSettlements.com Interviews Veterans Benefits Attorney Shanin Specter about Recent VA Hospital Reports 4Health News:LawyersandSettlements.com Interviews Veterans Benefits Attorney Shanin Specter about Recent VA Hospital Reports 5
... rates in South, Southwest; lowest rates in Northeast, government reports ... rate in the United States increased in 26 of the ... country, according to a new government report. , Back ... Prevention reported that the teen birth rate for the entire ...
... recognized inpatient treatment center, is pleased to announce its plans ... is just a few of the ways Seabrook ... possible and that treatment works. Seabrook House,s vision is to ... to educate the public at large in an effort to ...
... Top Government Officials Will Explain Regulatory Plans for Cutting-Edge Technology ... , DC . WASHINGTON, Jan. 7 ... goods last year. By 2014, the market will grow to ... and therapeutics will be sold--up from more than $3 billion ...
... more and more Michigan residents,losing employer-sponsored health coverage, the ... To ease the burden, the Blue Cross,Blue Shield ... in matching,funds for projects that improve health care access ... "Fundable projects for the uninsured include creative and novel ...
... teenage boys don,t seem to be as susceptible, study suggests ... spend more than two hours of "screen time" a day ... to be physically fit, a new Australian study finds. , ... more likely to be able to "sit and be fit," ...
... COLUMBIA, Mo. There is no cure for spinal ... weakening of muscles and is the leading genetic cause ... discovered a new therapeutic target that improves deteriorating skeletal ... muscle strength, improved gross motor skills and increased the ...
Cached Medicine News:Health News:Teen Birth Rate Up in 26 States in 2006 2Health News:Seabrook House Embraces the New Year with New Programs 2Health News:Seabrook House Embraces the New Year with New Programs 3Health News:Food and Drug Law Institute Sponsors Major Conference on Nanotechnology Law, Regulation and Policy 2Health News:Food and Drug Law Institute Sponsors Major Conference on Nanotechnology Law, Regulation and Policy 3Health News:Food and Drug Law Institute Sponsors Major Conference on Nanotechnology Law, Regulation and Policy 4Health News:$1 Million Available to Help Michigan's Uninsured Receive Care 2Health News:More 'Screen Time' Linked to Poor Fitness in Girls 2Health News:Researchers discover target that could ease spinal muscular atrophy symptoms 2
(Date:7/24/2014)... DALLAS , July 24, 2014  Market ... of IVD Insights™ LabFile , a data ... the US clinical laboratory universe and identifying target ... is a proprietary database that provides IVD manufacturers ... clinical tests, relying on clear and consistent definitions ...
(Date:7/24/2014)... 24, 2014 HIGHLIGHTS:Q2 2014 Results (all ... , Reported sales increased 3% to $701 million.  Sales grew ... added one percentage point to sales growth. , By ... in Applied and 1% in SAFC Commercial. , Reported ... an increase of 13%.  Adjusted diluted EPS in Q2 2014 ...
(Date:7/24/2014)... DIEGO , July 24, 2014   ... announced today a co-promotion agreement with Illumina to ... genome sequence data for precision medicine and clinical ... pharmaceutical companies, through Illumina,s sales force, a solution ... platform for data analytics and storage, and Cypher ...
Breaking Medicine Technology:MDxI Launches Data Resource Setting New Standard for Defining and Targeting US Clinical Laboratory Universe 2Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 2Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 3Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 4Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 5Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 6Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 7Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 8Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 9Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 10Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 11Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 12Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 13Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 14Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 15Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 16Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 17Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 18Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 19Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 20Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 21Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 22Cypher Genomics and Illumina Enter Agreement to Facilitate Genomic Biomarker Discovery 2Cypher Genomics and Illumina Enter Agreement to Facilitate Genomic Biomarker Discovery 3
... Alpharma Inc.,(NYSE: ALO ), a ... its Phase III pivotal efficacy trial that ... naltrexone,hydrochloride) capsules provided significant pain relief in ... osteoarthritis of the hip or knee compared,to ...
... Ardea Biosciences, Inc.,(Nasdaq: RDEA ) today announced ... mitogen-activated ERK kinase (MEK) inhibitor, RDEA119,at the American College ... & Convention Center in Orlando., ... October 7, 2008 from 10:30 a.m. - 4:00 p.m. ...
Cached Medicine Technology:Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 2Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 3Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 4Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 5Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting 2
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
25L...
This fixed-volume digital micropipet is used to accurately measure and transfer 50 microliters of solution....
50L...
Medicine Products: